Introduction
Imatinib mesylate (imatinib), a specific inhibitor of BCR-ABL tyrosine kinase, has shown remarkable results for patients with chronic myelogenous leukaemia (CML) in chronic phase. The rate of a complete cytogenetic response (CcyR), which means disappearance of the Philadelphia (Ph) chromosome, is more than 40% in patients after failure of interferon alpha (IFN) 1 and more than 75% in newly diagnosed patients. 2 Although the standard dose of imatinib for chronic phase is 400 mg/day orally, some CML patients cannot tolerate this dosage because of thrombocytopenia, oedema and skin rash 3, 4 and dosage is set at ≤ 300 mg/day. According to interferon studies involving CML patients, those with CcyR have a > 70% survival at 10 years. 5, 6 CML patients with major or complete cytogenetic response with imatinib have better survival than those with minor or no cytogenetic response, 1 After obtaining informed consent, the patient was admitted to our hospital for combination chemotherapy with IFN and imatinib orally on 11 April 2002. At that time, haematological examination showed a WBC of 5.1 × 10 9 /l (neutrophils 57.4%, eosinophils 2.8%, basophils 1.1%, monocytes 9.2%, lymphocytes 29.5%), Hb 13.4 g/dl and a platelet count of 173 × 10 9 /l. Bone marrow aspirate showed relative hypocellularity with normal maturation. Chromosome analysis of bone marrow cells revealed that 16 of 20 analysed cells had 46,XY,t(9;22)(q34;q11) (Fig. 1) . Major BCR/ABL chimeric transcript was 4.5 × 10 5 copy/100 ng RNA using the real time polymerase chain reaction (RT-PCR) (Fig. 1) . Simultaneous administration of IFN 5 MIU, three times a week, and imatinib 200 mg/day orally was started on 12 April (Fig. 1) , although an examination of bone marrow cells was unavailable because of dry tapped bone marrow. The Ph-chromosome disappeared from the bone marrow cells and the major BCR/ABL chimeric transcript was not detected by RT-PCR on 9 January 2003 (Fig. 1) . The disappearance of the major BCR/ABL transcript from the patient's bone marrow cells was confirmed by serial RT-PCR examination in January 2004, July 2004 and January 2005 (Fig. 1) , although nested RT-PCR examination has not been undertaken.
Haematological adverse effects of this combination drug therapy were grade 2 neutropenia and grade 1 thrombocytopenia (Fig. 2) . As shown in Fig. 2 
Discussion
In early 2002, the reported CcyR rate of imatinib was 41% in 454 patients with chronic-phase CML after failure of IFN therapy. 1 To obtain a second CcyR in our patient, possible treatment options were as follows: change the IFN schedule from every other day to every day; switch to imatinib 400 mg/day; or add other drugs as part of a combination therapy with IFN. The patient refused to alter the IFN schedule because of muscle cramp, and imatinib treatment was questionable because < 50% of patients attain CcyR. 1 An in vitro study has shown that the combination of IFN and imatinib is additively or synergistically effective for the Ph-positive leukaemia cell line. 7 Preliminary results of a study examining combination therapy with low-dose IFN and imatinib 400 mg/day indicate that the combination is more myelosuppressive than imatinib alone. 8 Based on this information, we planned a combination therapy with lowdose IFN (5 MIU, three times weekly) and lowdose imatinib (200 mg/day) for this patient. Our institutional review board approved this therapeutic plan in March 2002. The effect of combination therapy in this patient was quick and durable, i.e. a CcyR achieved by 3 months, and a CmoR achieved by 9 months and continuing for 2 years. In the phase 1 study of imatinib, only one of seven patients treated with 200 mg/day had a cytogenetic response. On the other hand, 12 of 27 cases treated with imatinib 200 mg plus pegylated-interferon alpha-2b (PEGIntron™) subcutaneously had a major cytogenetic response, suggesting that the combination is more potent in inducing a cytogenetic response than imatinib alone. 9, 10 In terms of the molecular response, no case of CmoR with imatinib 200 mg/day alone has been reported. Therefore, the combination therapy per se is considered effective for this durable molecular response, at least in this patient. Preliminary results of a combination study of imatinib and low-dose IFN showed no increase in non-haematological toxicities but were more myelosuppressive than imatinib alone 8 and no patient was able to tolerate a daily dose of 400 mg imatinib with 5 MIU IFN. 10 No cytogenetic or molecular responses were reported. A phase I/II study with PEGIntron™/week (subcutaneous) plus imatinib 400 mg/day (oral) enrolled 49 patients with chronic phase CML. 10 Thirtyeight patients (78%) experienced grade 3/4 haematological toxicity and 11 patients (22%) reported grade 3/4 nonhaematological toxicity. Twenty-seven of 46 evaluable patients (59%) had to interrupt therapy and required an adjustment of imatinib dosage to 200 mg. Cytogenetic data at the 2-month follow-up point revealed that three of 21 patients achieved a major response and 10 of 20 patients a minor response. Another phase I/II study with PEGIntron™/week plus imatinib 400 mg/day showed 45 of 76 treated patients discontinued therapy because of haematological (30% of the patients) and non-haematological (29% of the patients) adverse effects. 11 A CcyR was obtained in 53 of 76 patients (70%) and a CmoR was also reported in 11 of 76 patients (14%). A combination study with pegylatedinterferon alpha-2a (Pegasys ® )/week subcutaneously and imatinib 400 mg/day was conducted in 32 patients with chronic-phase CML. 12 Grade 3/4 cytopenias were observed in 13 of the 32 patients and grade 3 nonhaematological adverse effects were seen in five patients. Patients received 71% of the scheduled Pegasys ® and 95% of the imatinib doses. A CcyR was observed in 63% of the patients and some molecular response was reported. Thus, the adverse effects of a combination therapy with imatinib of J Takeuchi, K Miura, Y Hatta et al. Molecular CR in CML with low-dose imatinib and interferon 400 mg/day and IFN or pegylated-interferon seem to be toxic, although cytogenetic and molecular responses are expected.
Our combination regimen with low-dose IFN and low-dose imatinib can be continued for more than 2 years with minimal adverse effects, and a CmoR has been maintained. Although only one patient is described here, this report may be of assistance in planning the dosage and schedule of IFN and imatinib in future combination studies in CML patients in chronic phase.
